Genomic features associated with clinical outcomes
SECONDARY
In an effort to refine future selection of patients for this risk-adapted treatment approach, a secondary objective of the study was to assess whether the presence of a set of genomic alterations in baseline TURBT tissue would enhance the positive predictive value of cCR. Tumor-only targeted DNA sequencing of pre-treatment TURBT tissue was available from 73 of 76 patients (Fig. 